China Innovative Drug Weekly: RNA, ADC, CAR-T and GLP-1 Drive Global Expansion
China Innovative Drug Weekly: RNA, ADC, CAR-T and GLP-1 Drive Global Expansion
Against the backdrop of a global pharmaceutical industry increasingly driven by innovation, Chinese biopharmaceutical companies are accelerating breakthroughs across RNA therapeutics, ADCs, CAR-T, and metabolic diseases.
From platform innovation to clinical progress and cross-border licensing, the industry is entering a multi-driven phase integrating technology, clinical validation, and commercialization.
👉 Related insights:
Global pharmaceutical regulatory trends
1. RNA Therapeutics: Extrahepatic Delivery Gains Momentum
Vivatides Therapeutics completed a $54M Series A financing to advance extrahepatic RNA delivery platforms.
Delivery beyond the liver remains a core bottleneck in RNA therapeutics, especially for:
- Cardiovascular diseases
- CNS indications
- Metabolic disorders
This highlights strong investor confidence in platform-driven innovation.
2. Global Expansion: MENA Becomes Strategic Entry Point
Xuanzhu Biopharma signed a licensing deal covering 20+ MENA countries, exceeding $100M in milestones.
This reflects a shift toward:
- Emerging markets
- Faster regulatory pathways
- Unmet medical needs
👉 Explore supply-side dynamics:
Pharmaceutical supply chain insights
3. ADC Progress: Commercialization Milestone
DB1303 (HER2 ADC) has been accepted for review by China CDE.
Previously licensed to BioNTech (up to $1.5B), this marks a key step toward commercialization.
China’s ADC ecosystem is evolving through:
- Linker innovation
- Payload optimization
- Antibody engineering
4. Cell Therapy: CAR-T Moves into Solid Tumors
Oricell Therapeutics raised $110M to advance GPC3-targeting CAR-T therapy.
While CAR-T is established in hematologic cancers, solid tumors remain a major frontier.
👉 Related oncology developments:
Oncology innovation trends
5. Metabolic Disease: Oral GLP-1 Advances
Ascletis is developing an oral GLP-1 + amylin combination therapy.
Goal:
- Replace injections
- Improve adherence
- Maintain efficacy
6. Gene Therapy: AI-Designed AAV Enters Commercial Phase
Dyno Therapeutics licensed an AI-designed AAV capsid to Astellas.
Deal structure:
- $15M upfront
- Milestones + royalties
This demonstrates the growing role of AI in gene delivery optimization.
7. Gene Editing: CRISPR Moves Forward
Bendao Gene advanced multiple CRISPR programs:
- BD111 (Phase II)
- BD211 (thalassemia)
- BD312 / BD115 (IND stage)
Gene editing is expanding beyond rare diseases into broader applications.
👉 Explore rare disease landscape:
Rare disease innovation
Key Industry Trends
1. High-Barrier Innovation Focus
- RNA delivery
- Solid tumor CAR-T
- AI-driven gene therapy
2. Diversified Globalization
- Expansion beyond US/EU
- Growth in emerging markets
3. Clinical Value First
- Efficacy
- Safety
- Patient outcomes
Role of Global Supply & Access
As innovation accelerates, global accessibility becomes the key bottleneck.
Integrated solutions such as
pharmaceutical import and export services
are essential to ensure efficient cross-border delivery.
Cold chain infrastructure also plays a critical role, especially for biologics and cell therapies.
Solutions like
cold chain logistics for biologics
support safe global transport.
Conclusion
Chinese innovative drugs are rapidly transitioning from R&D breakthroughs to global integration.
In this process, platforms providing
cross-border pharmaceutical supply solutions
such as
https://dengyuemed.com/
are helping bridge innovation and patient access worldwide.
As demand grows for therapies including immunotherapy, ADCs, and gene therapies, reliable global supply systems will be increasingly critical.
China is no longer just participating in global pharma innovation—it is actively shaping it.
Contact & Global Access
For drug sourcing, regulatory support, and global distribution:
👉 https://dengyuemed.com/